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ABSTRACT 
Remodeling process results from the action of the tissue-forming osteoblasts and the tissue-resorbing osteoclasts which work together in 
certain cell units called basic multicellular units (BMUs). The local regulation of the bone cell function includes  the receptor activator of 
nuclear factor κB ligand (RANKL)/ receptor activator of nuclear factor κB (RANK) / Osteoprotegerin (OPG) system. These molecules 
are key factors linking bone formation to resorption during the bone remodeling process. The OPG/RANKL/RANK system has a role in 
the pathogenesis of bone loss by modulating RANK-induced osteoclastogenesis. This role has provided the rationale for durg 
development that treat the bone diseases. Systemic OPG therapy was used for bone disease treatment parenteral.   According to our 
knowledge that got from researches, there is no study has been done to explore the use of the local delivery system of OPG in the bone 
resorption treatment. This approach may have similar osteogenic potential in bone defects that might be capable of treatment the bone 
loss. 
Keywords: Osteoprotegerin, bone remodeling, bone diseases. 
 
1. INTRODUCTION 
 The discovery of nuclear factor κB ligand (RANKL)/ 
RANK/OPG signaling pathway that has a role in the pathogenesis 
of bone resorption by modulating RANK-induced 
osteoclastogenesis have provided the rationale for the 
development of drugs to treat bone diseases [1]. 
 OPG is a secretory glycoprotein of the tumour necrosis 
factor (TNF) receptor and plays an important role in the contol of 
bone resorption [2]. OPG has one ligand namely RANKL. 
RANKL is a Type 2 transmembrane glycoprotein that belongs to 
the TNF family of cytokines. RANKL is showed on the surface of 
osteoblasts, stromal cells, and T cells. The bound between 
RANKL and RANK stimulates differentiation of 
monocyte/macrophage progenitor cells into active and matured 
osteoclasts via numerous signaling pathways [3].  
 The role of OPG in the pathological aspects of bone 
diseases, such as osteoporosis associated with estrogen deficiency 
and periodontal disease, has been well established.  Since the 
discovery of OPG as an inhibitor of osteoclast activity and 
maturation, it has opened up a new research exploration using 
OPG as a potential therapeutic agent for the treatment of bone 
diseases. Here, we reviewed the pathways of   OPG in bone 
diseases and its application in therapeutic perspectives. 
 
2. OSTEOPROTEGERIN (OPG) 
 OPG has been identified by Simonet and co-workers [4] as 
a secretory glycoprotein form of the superfamily of tumor necrosis 
factor (TNF) receptors. It inhibits osteoclast maturation and 
protects the physiological process of osteoclast  in bone 
remodeling and ovariectomy-associated bone resorption. 
 The name osteoprotegerin derived from Latin os for bone 
and protegere to protect [5]. It is also named as TNF receptor-
related molecule-1 (TR-1), tumor necrosis factor receptor 
superfamily member 11B (TNFRSF11B), osteoclastogenesis 
inhibitory factor (OCIF)  and follicular dendritic cell receptor- 
(1FDCR-1).  
OPG mRNA is expressed in bone, skin, liver, lung, stomach, 
placenta, brain and the range of other tissues. The site(s) at which 
it exerts its biological function is unnecessarily prdictable by the 
site of its expression.  The binding of RANKL to RANK exerts its 
biological function as OPG is a secreted protein [4]. 
OPG has no transmembrane and cytoplasmic domain as most of 
the TNF superfamily receptors and is secreted as soluble protein. 
OPG is synthesized by osteoblast as a propeptide from which the 
signal peptide (with 21 amino acids) separates, generating a 380-
amino acid matures peptide. It has two terminals, N and C 
terminus and has seven major domains (domains 1–7).  
 At the N-terminus of OPG is death domains (D1–D4) 
which are cysteine-rich structures with a characteristic of the 
extracellular domains of the TNFR family proteins, these domains 
are essential for biological activity. At the C-terminus, it has two 
death domains (D5-D6) that share structure features with the death 
domains of the TNF receptor p55, Fas and TNF-related apoptosis-
inducing ligand (TRAIL) receptor, all mediate apoptosis signals. 
Furthermore, C- terminus has domain 7 which has the heparin 
binding site. Binding to heparin or heparin-like molecules is  
important for such growth factors as a basic fibroblast growth 
factor to work.  
 Despite it does not correlate with the biological activity, 
but changes in heparin-binding with proteins affect stability, the 
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rate of clearance, and target cell specificity.  Domain 7 is also 
responsible for the dimerization of OPG by disulfide bond and the 
dimer TNF protein is a more potent inhibitor [4-7]. 
OPG exists as homodimeric and monomeric forms. Both of these 
forms have similar potency in osteoclastogenesis inhibtion in vitro 
as reported by Tomoyasu and co-workers [8].  But in another 
study, dimeric form of OPG is a more potent RANKL inhibitor 
than the monomeric form, this study was reported in Schneeweis 
and co-workers [9].  
OPG production is imitated by 1α, 25-dihydroxyvitamin D3, 
estrogens, pro-inflammatory cytokines such as interleukin-1 (IL-1) 
and TNF-α as well as transforming growth factor-β (TGF-β). OPG 
production is suppressed by parathyroid hormone and 
glucocorticoids [10, 11]. 
 
3. BIOLOGICAL FUNCTIONS OF OPG 
 OPG has almost one ligand, RANKL. RANKL is a type 2 
transmembrane glycoprotein that belongs to the TNF family of 
cytokines. It is expressed on the surface of osteoblasts, stromal 
cells and T cells [12]. RANKL can be expressed in two forms: as a 
membrane anchored form and as a soluble form. These two forms 
can work as potential ligands that can interact with RANK and/or 
OPG receptors with the same biological activity [13].  
 In bone, RANKL specifically bind the RANK receptors, 
which are a type I transmembrane protein of the TNF receptor 
superfamily [14]. RANK receptor expressed on osteoclasts, the 
surface of hematopoietic osteoclast progenitors, mammary gland 
epithelial cells, chondrocytes, mature T cells, trophoblast cells, 
dendritic cells, and hematopoietic precursors [15-17].  
 The RANK/RANKL binding stimulates the differentiation 
of the monocyte/macrophage progenitor cells to osteoclasts 
through the activation of numerous signaling pathways involved in 
the osteoclast differentiation, activation and survival [2, 3].  
As the binding of RANKL to RANK on pre-osteoclasts and 
osteoclasts is essential for their maturity and activity, OPG deters 
binding of RANKL to RANK. Subsequently, this binding inhibits 
the activation of osteoclast and osteoclastogensis and bone 
resorption. 
 Moreover, OPG also plays a key role in cell survival by its 
interactivity with TNF-related apoptosis inducing ligand (TRAIL). 
The binding of the OPG to the TRAIL and RANKL has similar 
affinities. As a result of the TRAIL/OPG interaction, TRAIL-
induced apoptosis in several types of cells and many cancer cells 
is inhibited [18]. This could explain the reason for the phenomena 
of stimulation OPG production by tumor cells [19]. Pritzker and 
co-workers [20] considered the OPG as a survival factor for 
human microvascular endothelial cell survival as it could bind and 
block TRAIL-induced apoptosis.  
 
4. ROLE OF OPG IN THE BONE DISEASE PATHOGENESIS 
 Various studies suggest that different bone diseases are 
related to alterations in OPG/RANKL/RANK system. Here we 
summarize several bone diseases associated with 
OPG/RANKL/RANK abnormalities that are estrogen secretion 
deficiency associated with Osteoporosis, drug-induced 
osteoporosis, hyperparathyroidism, Paget’s disease, chronic 
inflammatory diseases, autoimmune diseases, osteopetrosis, bone 
tumors and metastases and cushing syndrome. 
4.1. Estrogen secretion deficiency associated with osteoporosis. 
 Estrogens and androgens have direct effects on osteoclasts 
and inhibit bone resorption in vitro as well as inhibit the 
production of the pro-resorptive cytokine, interleukin (IL)-6 [21, 
22]. The estrogen has a major role in the bone antiresorbing 
activity by stimulating OPG expression in osteoblasts. Estrogens 
induce the expression of the OPG gene in vitro and stimulate the 
OPG production from osteoblasts and inhibit the RANKL 
production [23].  The decrease of the estrogen secretion associated 
with decreasing the ovarian function leads to the decrease of the 
OPG production in the source cells and subsequently increase 
bone resorption [24]. 
4.2. Drug-induced osteoporosis. 
 The most frequent secondary form of osteoporosis is 
Glucocorticoid-induced osteoporosis. Glucocorticoids down-
regulate OPG expression and increase the RANKL expression 
[25]. After glucocorticoid exposure, the rise in the osteoblastic 
RANKL/OPG ratio is associated with enhanced osteoclastogenesis 
[26].   
 Immunosuppressants such as cyclosporine A, rapamycin, 
and tacrolimus [27-29] have also been involved in the 
pathogenesis of post-transplant osteoporosis. These agents have 
been presented to significantly decrease OPG mRNA levels and 
protein secretion by osteoblast precursor cells in a dose-dependent 
fashion. It also stimulates RANKL mRNA levels in marrow 
stromal cells, thus substantially increasing the RANKL/OPG ratio 
and induce osteoclastogenesis [29]. OPG serum levels were 
positively correlated with serum levels of osteocalcin, parathyroid 
hormone, and creatinine. After renal transplantation, patients 
receiving cyclosporine and glucocorticoids, serum levels of OPG 
decreased significantly after 2 weeks from receiving drugs 
compared to baseline levels while creatinine clearance increased 
[30, 31].    
4.3. Hyperparathyroidism (PTH). 
 Parathyroid hormone stimulates RANKL expression and 
inhibits OPG production by osteoblasts, and thus promotes 
osteoclastogenesis [32]. 
The effect of PTH on the production of OPG is controversial. PTH 
decreases OPG secretion by the osteoblast in most in vitro studies 
[33, 34]. However, in vivo observations are conflicting, serum 
OPG is not decreased in patients with hyperparathyroidism, not 
changed pre- or postoperatively [35]. On the other side, treatment 
of rats with PTH decreased OPG mRNA levels in rat femur 
metaphyseal and diaphyseal bone [31]. One more study showed 
that hyperparathyroidism is accompanied by a high serum 
concentration of OPG and RANKL as well as a low OPG/RANKL 
ratio. Both treatments with alendronate or parathyroidectomy 
reduce bone resorption, and increase the OPG / RANKL ratio [36, 
37].  
 A new standard of osteoclast regulation is being developing 
based on the different effects of PTH on RANKL and OPG at 
different stages of osteoblast development.  Osteoclastogenic 
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activity of PTH takes place primarily by suppression of OPG gene 
expression in first osteoblasts and raising of RANKL gene 
expression in mature osteoblasts [38]. 
4.4. Paget’s disease. 
 The genetic polymorphisms of the OPG gene 
(TNFRSF11B) and RANK gene (TNFRSF11A) have been 
associated with Paget’s disease of bone. They contribute to 
increasing the risk for developing the Paget’s disease which is 
characterized by increased bone resorption by osteoclasts and 
uncontrolled bone remodeling [39]. 
Juvenile Paget’s disease is a rare, autosomal recessive bone 
disease identified  by greatly accelerated bone turnover that 
presents in infancy or childhood. Juvenile Paget’s disease can 
result from osteoprotegerin deficiency caused by homozygous 
deletion the gene that encodes osteoprotegerin [40, 41].  
4.5. Chronic inflammatory diseases.  
 The T cells seem to be the link between the bone resorption 
and inflammation. RANKL expression occurs at the surface of 
activated, but not quiescent, murine T cells. RANKL derived from 
T cell has as a signal included in optimal T cell activation. Also, T 
cell derived RANKL can regulate the osteoclast development and 
activation resulting in bone resorption so it plays a major role in 
the bone remodeling [42].  RANKL expression is upregulated by 
many soluble factors affecting bone loss, including the 
proinflammatory cytokines and interleukin-1 and TNF-α. T cells 
presents a cell-surface membrane-bound RANKL which is splited 
by metalloproteinases into a soluble form. Possibly, there are some 
functional differences between membrane-bound and soluble 
RANKL, with cell-bound OPGL being more functional mediators 
of osteoclastogenesis when measured by in vitro assays [42, 43]. 
Proinflammatory cytokines such as IL1 and IL6 and TNF- α 
increase the production of the RANKL and decrease the OPG 
production. These mediators and change of OPG production are 
associated with the chronic local inflammation and viral 
infections. [44, 45]. OPG act as a decoy receptor for RANKL, 
competing with RANK for binding with RANKL, effectively 
inhibiting osteoclastogenesis. Therefor, the evaluation of RANKL 
levels with OPG levels must    accompanied as the balance of both 
will determine whether  osteoblastic or osteoclastic activity 
dominates [44, 46]. 
4.6. Periodontitis. 
 In the normal periodontium, OPG is expressed by cultured 
human gingival fibroblasts, periodontal ligament cells and dental 
pulp cells, but not epithelial cells [45]. OPG is continually 
released by resident periodontal fibroblasts and potentially 
endothelial cells [47]. 
 Macrophages and T lymphocytes that infiltrate the gingival 
connective tissue in periodontitis release inflammatory mediators 
for example, IL-1, IL-6, TNF-α and prostaglandin E2. These 
mediators stimulate osteoblasts to produce RANKL and induce 
bone resorption indirectly. T lymphocytes can also promote 
alveolar bone resorption by direct production of RANKL [48].  
The various forms of periodontitis are differentially regulated by 
the expression of RANKL and OPG and it acts as indicative of 
disease occurrence [49]. 
 Crotti and co-workers [50] compared the RANKL and 
OPG expression in the granulomatous tissue adjacent to the areas 
of alveolar bone loss from periodontitis patients to the tissue 
without periodontitis. Their results revealed the significantly 
higher levels of RANKLprotein in the periodontitis tissue. 
Mogi et al. [51] and Bostanci et al [49] studied the alteration of 
RANKL and OPG levels in gingival crevice fluid (GCF) of 
patients with periodontitis. They found that an increase of 
RANKL/OPG in GCF from periodontitis patients.  
 In the same line Koide and coworkers [52] reported that the 
alveolar bone loss associated with OPG-deficient mice may be 
prevented by OPG which is produced locally.  
4.7. Periapical disease. 
 OPG and RANKL have been identified in odontoblasts, 
ameloblasts, pulp cell lines, and periodontal ligament cells, and 
their expression is considered to play a role in osteoclastogenesis 
and bone resorption [53, 54]. In periapical disease, abnormal 
RANKL and OPG expression are detected, RANKL level is 
increased, OPG level is decreased significantly which associated 
with the bone absorption. The bone absorption in the periapical 
cyst is more active than in periapical granuloma [55]. 
4.8. Autoimmune diseases. 
 The RANKL/RANK/OPG system plays as an important 
link between the immune system and bone metabolism. The 
functioning of the OPG/RANKL system is identical to that of the 
interleukin–cytokine system [56].  
 Rheumatoid arthritis is a chronic disease that is defined by 
progressive synovial inflammation and joint destruction. The 
RANK/RANKL/OPG system plays a significant part in the 
pathogenesis of local and generalized bone loss in rheumatoid 
arthritis [57]. The synovial fibroblasts, osteoblastic stromal cells, 
and activated T-cells express the RANKL lead to increase the 
RANKL/OPG ratio,that results in enhancing osteoclastogenic in 
erosive arthritis [58, 59]. Otherwise, some studies have shown that 
serum levels of OPG and RANKL in patients with rheumatoid 
arthritis are higher than those in healthy people. These can be 
explained by anti-TNF therapy, whereby regulates the 
OPG/RANKL balance by stimulating the bone erosion in arthritis 
[59, 60]. 
4.9. Osteopetrosis. 
 Osteopetrosis is a rare inherited disorder whereby bone 
mass increase as a result of decreasing the osteoclastogenesis and 
bone resorption [61].  OPG, RANKL and their signaling pathway 
may play a major role in the pathogenesis of osteopetrosis. The 
inhibition effect of OPG on osteoclastogenesis was approved in 
vitro and in vivo [4]. 
4.10. Bone tumors and metastases.  
 In bone metastases, the RANK / RANKL pathway is 
essential in the pathology of bone destruction.  Bone tumor cells 
can activate the osteoclasts by causing increased RANKL levels 
and/or decreasing OPG levels locally, resulting in excessive 
osteoclast activity [62, 63]. In severe osteolysis, RANKL/OPG 
ratio is increased and involved in the development of benign and 
malignant bone tumors and the progress of osteolytic lesions by 
tumor metastases [64, 65]. RANKL expression is increased in 
bone metastases associated with different types of solid tumors, 
including breast cancer while the expression of OPG is inhibited. 
These changes caused by secretion the factors such as IL-1, IL-11 
and PGE2 by tumor cells present in the bone marrow [66, 67]. 
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4.11. Cushing syndrome.  
 Cushing syndrome defined as the signs and symptoms 
associated with prolonged exposure to incorrectly high levels of 
the hormone cortisol. This can result from diseases that caused the 
excess cortisol, adrenocorticotropic hormone levels, taking 
glucocorticoid drugs [68].  
Serum OPG levels also positively correlated with morning serum 
cortisol. In patients with Cushing syndrome, serum OPG levels are 
higher than healthy control subjects, but it remained unchanged 
after the recovery, even the bone is restored. The elevation of OPG 
level could be due to persistent damage to the cardiovascular 
system by glucocorticoid [69-71].   
 
5. OVERVIEW OF THERAPEUTIC PERSPECTIVES OF OPG IN BONE DISEASES 
 As the OPG has a key role in the bone diseases, there are 
various experimental and clinical trials on the use of OPG in 
treatment of different bone diseases.  It was previously reported 
that OPG-chitosan matrices and gel increase the in vitro 
proliferation of normal human osteoblasts and fibroblasts cells that 
used later to treat the critical size defects on parietal bone of 
rabbit. The results of this studies showed that bioresorbable OPG-
chitosan material induced the formation of a significant quantity of 
bone in a critical-sized parietal bone defect in a rabbit model [72-
74]. 
 Simonet et al. [4] and Yasuda et al. [6] reported that the 
increasing in bone mass in mice after treatment with OPG at 10 
mg/kg/day for 7 days and 24 mg/ kg/day for 14 days.   
Furthermore, OPG treatment at a dose of 5 mg/ kg/day for 14 days 
has been completely prevented ovariectomy-induced bone loss in 
rats [4]. There is another study confirmed the hypocalcemia 
effects of OPG after injection in normal rats. The result showed 
that increases of density of bone mineral and volume of bone 
accompanied by a decrease of osteoclast number. The facts 
suggested that the reduction of the calcium concentration in serum 
of normal rats by administration of OPG is due to suppression of 
bone resorption by inhibition of osteoclastogenesis, especially 
maturation of osteoclasts [8].  
 Bolon and co-workers transfer OPG gene mediated vehicle 
by a single injection of a recombinant adenovirus carrying the 
OPG-Fc gene, prevents bone density loss induced by ovariectomy 
period [75]. In addition, a single intravenous injection of OPG in 
young growing rats leads to a significant increase in bone volume 
and density, which are associated with suppression of osteoclastic 
bone resorption [76]. 
 Other preclinical studies demonstrated a potential 
therapeutic role of OPG in the prevention and reduction of lytic 
bone lesion associated with skeletal tumor. Lamoureux et al. [77] 
suggested the targeting of RANKL may has the potential to 
modify the osteosarcoma  and suppress its development. 
In experimental periodontitis, human OPG has strong preventive 
effects on alveolar bone loss in rats [78]. Yao et al. [79] revealed 
that OPG with BMP-2 improves osteoblastogenesis and new bone 
formation by recruitment of mesenchymal stem cells [79]     
 OPG treatment is used in preclinical bone metastasis 
models. The result revealed that the proliferation of tumor cell is 
decreased and apoptosis of tumor cell osteoclast activity is 
decreased. Whereby the bone turnover and the pro-tumor growth 
factors releasing from the bone matrix are prevented [64]. 
 Additionally, there are a few clinical trials on the use of 
OPG systemically. One of these studies is done by using a single 
subcutaneous dose of human recombinant OPG (3 mg/kg) in post-
menopausal women [80, 81]. It was stated that biochemical 
markers of bone resorption have reduced and OPG can reduce 
bone turnover. 
 Another study performed by Body et al. [82], who used 
recombinant OPG in patients with bone disease related to breast 
carcinoma or multiple myeloma. The results indicated that 
recombinant OPG is effective in reducing bone resorption marker 
levels as an accepted treatment for these diseases. 
 
6. CONCLUSIONS 
 Bone resorption-related diseases, such as periodontitis, 
osteoporosis or rheumatoid arthritis, affect many people 
worldwide. New doors have been opened for bone research and 
drug development. The different studies  illuminate the fact of that 
OPG regulates osteoclastogenesis via the RANKL-OPG pathway.  
Thus, enhancing OPG production may be accompanied with an 
increase in bone mass. 
 Since the discovery of OPG as an inhibitor of osteoclast 
activity and maturation, it has opened up a new research 
exploration using OPG as a potential therapeutic agent for the 
treatment of bone diseases. Up to our knowledge, there is a few 
research carried out to explore the use of local OPG therapy in the 
treatment of bone resorption. As a  critical therapeutic concern, it  
is to  target  specifically  the  bone tissue  to  avoid  prospective 
undesired effects  on  other tissues.  Systemic therapy may lead to 
unwanted side effects, therefore local therapy of OPG may be 
efficient as an alternative therapy.   
 Despite  the interest  of  the  various studies targeting  the  
OPG  pathways  in  skeletal  diseases,  further  preclinical and  
clinical  studies  are  needed. One possible approach is the 
development of local delivery of OPG that may have similar 
potential in treatment of bone loss. 
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